Disclosed herein are CpG conjugated nanoparticles for immunotherapy and photothermal therapy. The composition comprises class B CpG conjugated nanoparticles and/or a class C CpG conjugated nanoparticles where the class B CpG conjugated nanoparticles comprises a nanoparticle core and a class B CpG conjugated thereto and the class C CpG conjugated nanoparticles comprises a nanoparticle core and a class C CpG conjugated thereto.

Disclosed herein are CpG conjugated nanoparticles for immunotherapy and photothermal therapy. The composition comprises class B CpG conjugated nanoparticles and/or a class C CpG conjugated nanoparticles where the class B CpG conjugated nanoparticles comprises a nanoparticle core and a class B CpG conjugated thereto and the class C CpG conjugated nanoparticles comprises a nanoparticle core and a class C CpG conjugated thereto.

The present invention relates to a composition for inhibiting the growth of cancer stem cells, and a use thereof. A WDR34 inhibitor of the present invention inhibits the conversion of cancer cells into cancer stem cells and exhibits activity of inhibiting self-renewal, invasion, and migration of cancer stem cells, and thus can be effectively used as a cancer cell growth or metastasis inhibitor or a cancer stem cell growth inhibitor.

The present invention relates to a composition for inhibiting the growth of cancer stem cells, and a use thereof. A WDR34 inhibitor of the present invention inhibits the conversion of cancer cells into cancer stem cells and exhibits activity of inhibiting self-renewal, invasion, and migration of cancer stem cells, and thus can be effectively used as a cancer cell growth or metastasis inhibitor or a cancer stem cell growth inhibitor.

Provided are novel piperazic acid containing peptide compound stereoisomer, solvate, or pharmaceutically acceptable salt thereof, method of preparing the same, and use thereof. The peptide compound, stereoisomer, solvate, or pharmaceutically acceptable salt thereof has activities of anticancer, anti-metastasis, and growth inhibition of resistant tumors, and thus may be used to prevent or treat various cancers or metastases of cancer.

This invention provides methods for near-instantaneously separating cells that have undergone RNA guided genome modifications into pre-templated instant partitions (PIPs) and using the PIPs to associate the guide RNAs with the gene expression level changes that resulted from the genome modification.

Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.

Provided herein are methods for treating cancers (e.g., inflammatory myofibroblastic tumor, anaplastic large cell lymphoma, and neuroblastoma) in pediatric patients using brigatinib, as monotherapy or combination therapy with one or more second therapeutic agents.

The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.

Methods of treating or preventing a disease or disorder are disclosed comprising administering to a subject in need thereof an effective amount of a nucleic acid compound comprising, or consisting of, a nucleic acid sequence capable of binding to a transferrin receptor (TfR) and an effective amount of an inhibitor of DNA synthesis. Also disclosed is a nucleic acid compound comprising, or consisting of, a nucleic acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein said nucleic acid sequence is at least 30 nucleotides in length and at most 50 nucleotides in length, and wherein the nucleic acid sequence is capable of binding to a transferrin receptor (TfR).